|
Placebo to match EDG-15400 25 mg or 50 mg Clinical Trials
1 actively recruiting trial across 1 location
Pipeline
Phase 2: 1
Top Sponsors
- Edgewise Therapeutics, Inc.1
Indications
- Heart Failure With Preserved Ejection Fraction1
- Heart Disease1
Birmingham, Alabama1 trial
A Study of EDG-15400 in Adults With Heart Failure With Preserved Ejection Fraction (EQUINOX-HFpEF)
Local Institution - 156
Phase 2
Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.
This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.